证券代码：300753 证券简称：爱朋医疗 公告编号：2024-042 江苏爱朋医疗科技股份有限公司 第三届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、 监事会会议召开情况 江苏爱朋医疗科技股份有限公司（以下简称"公司"）第三届监事会第九次会议通 知及会议材料于2024年10月18日以电话和邮件形式向公司全体监事发出，会议于2024 年10月28日在上海市闵行区联航路1188号3号楼公司会议室以现场结合通讯的方式召 开。本次会议应出席监事3人，实际出席监事3人，会议由公司监事会主席袁新闯先生主 持，会议出席人数、召集、召开和表决程序符合《公司法》等相关法律法规以及《公司 章程》的相关规定。 江苏爱朋医疗科技股份有限公司监事会 2024 年10月30日 - 2 - 1、审议通过《2024年第三季度报告》 监事会认为：董事会编制和审核《2024年第三季度报告》的程序符合法律、行政法 规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情况，没有虚 假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日于巨潮资讯网（ww ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-041 江苏爱朋医疗科技股份有限公司 第三届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 表决结果：7票同意，0票反对，0票弃权。 2、审议通过《关于聘任公司董事会秘书及证券事务代表的议案》 公司董事会同意聘任叶俞飞先生为公司董事会秘书，聘任黄秀秀女士为公司证券 事务代表。任期自本次董事会审议通过之日起至第三届董事会任期届满之日止。该议 一、董事会会议召开情况 江苏爱朋医疗科技股份有限公司（以下简称"公司"）第三届董事会第九次会议 通知及会议材料于2024年10月18日以电话和邮件形式向公司全体董事发出。会议于 2024年10月28日在上海市闵行区联航路1188号3号楼公司会议室以现场结合通讯的方 式召开。本次会议应出席董事7名，实际出席董事7名。会议由董事长王凝宇先生主持， 公司监事、高管列席了本次会议，会议出席人数、召集、召开和表决程序符合《公司 法》等相关法律法规以及《公司章程》的相关规定。 二、董事会会议审议情况 本次会议以记名方式投票表决，逐项审议以下议案： ...

Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the North American market [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8%, primarily due to increased marketing and R&D investments [3]. Market Expansion - The company successfully entered the European market, with initial sales exceeding expectations [4]. - A new distribution center was opened in Asia to support growing demand in the region [5]. - Strategic partnerships were formed with local retailers to enhance market penetration [6]. Product Development - Launched three new products in the tech segment, which have received positive customer feedback [7]. - R&D investment increased by 20% to accelerate innovation and product differentiation [8]. - The company plans to introduce a new line of eco-friendly products by the end of the year [9]. Operational Efficiency - Implemented a new supply chain management system, reducing delivery times by 15% [10]. - Automation initiatives in manufacturing led to a 10% reduction in production costs [11]. - Employee training programs were expanded to improve operational efficiency and reduce errors [12]. Sustainability Initiatives - Achieved a 25% reduction in carbon emissions through the adoption of renewable energy sources [13]. - Introduced a recycling program that has successfully diverted 30% of waste from landfills [14]. - The company committed to achieving net-zero emissions by 2030 [15]. Customer Engagement - Customer satisfaction scores improved by 5% due to enhanced after-sales support [16]. - Launched a loyalty program that has already attracted over 100,000 members [17]. - Social media engagement increased by 40%, driven by targeted marketing campaigns [18]. Risk Management - Identified potential supply chain disruptions and implemented contingency plans [19]. - Cybersecurity measures were strengthened to protect customer data and intellectual property [20]. - The company conducted a comprehensive risk assessment to mitigate financial and operational risks [21]. Corporate Governance - Appointed two new independent directors to the board, enhancing governance and oversight [22]. - Revised the company's code of conduct to align with global best practices [23]. - Conducted regular audits to ensure compliance with regulatory requirements [24]. Employee Development - Introduced a new leadership training program to develop future leaders within the organization [25]. - Employee retention rates improved by 8% due to enhanced benefits and career development opportunities [26]. - Launched a diversity and inclusion initiative to promote a more inclusive workplace [27]. Strategic Partnerships - Formed a joint venture with a leading technology firm to co-develop innovative solutions [28]. - Collaborated with a major logistics provider to optimize global distribution networks [29]. - Partnered with a non-profit organization to support community development projects [30].

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-040 江苏爱朋医疗科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 李晓玉女士简历 李晓玉，保荐代表人，管理学硕士，广发证券投行业务管理委员副总监。曾负责 或参与爱朋医疗、正海生物、恒辉安防、如通股份、万德斯等企业的改制辅导与上市 相关工作，具有扎实的资本市场理论基础与丰富的投资银行业务经验。 本次保荐代表人变更后，公司首次公开发行股票持续督导期间的保荐代表人为袁 海峰先生、李晓玉女士，持续督导期限截止至募集资金使用完毕为止。 公司董事会对刘磊先生在公司首次公开发行股票持续督导期间所做出的贡献表 示衷心的感谢！ 特此公告。 附件：李晓玉女士简历 江苏爱朋医疗科技股份有限公司董事会 2024年10月8日 附件： 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于2024年10月8日收到公 司首次公开发行股票的保荐机构广发证券股份有限公司（以下简称"广发证券"）出 具的《关于变更公司保荐代表人安排的通知》，广发证券原委派袁海峰先生、刘磊先 生担任公司 ...

江苏爱朋医疗科技股份有限公司 简式权益变动报告书 上市公司名称：江苏爱朋医疗科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：爱朋医疗 股票代码：300753 信息披露义务人：王凝宇 住所/通讯地址：上海市闵行区联航路1188号浦江智谷3号楼 股份变动性质：股份减少、持股比例下降（协议转让） 签署日期：2024 年 9 月 29 日 1 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收购管理办法》"）、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》（以下简称 "《第15号准则》"）及相关的法律法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反信息 披露义务人章程或者内部规则中的任何条款，或与之相冲突。 六、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重大遗漏，并对 其真实性、准确性、完整性承担个别和连带的法律责任。 2 | 第一节 | 释义 4 | | --- | --- | | 第二节 | 信息披露义务人 5 | | ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-039 江苏爱朋医疗科技股份有限公司 关于控股股东、实际控制人拟协议转让公司部分股份 暨权益变动的提示性公告 公司控股股东、实际控制人王凝宇先生保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。本公司 及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述 或重大遗漏。 特别提示： 1、江苏爱朋医疗科技股份有限公司（以下简称"公司"）控股股东、实际控制人王凝 宇先生于 2024 年 9 月 29 日与北京章泓私募基金管理有限公司（代表"章泓精选 1 号私募 证券投资基金"）（以下简称"章泓基金"）签署了《关于江苏爱朋医疗科技股份有限公 司之股份转让协议》。王凝宇先生拟以协议转让方式向章泓基金转让其持有的公司无限售 流通股 7,058,000 股，占公司总股本的 5.60%（以下简称"本次协议转让"）。 2、本次协议转让事项不触及要约收购，不构成关联交易。 3、本次协议转让后，公司控股股东、实际控制人王凝宇先生仍持有公司总股本的 ...

江苏爱朋医疗科技股份有限公司 简式权益变动报告书 上市公司名称：江苏爱朋医疗科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：爱朋医疗 股票代码：300753 信息披露义务人：北京章泓私募基金管理有限公司-章泓精选 1 号私募证券投资基金 基金管理人：北京章泓私募基金管理有限公司 管理人注册地址：北京市房山区北京基金小镇大厦 C 座 441 股份变动性质：股份增加、持股比例上升（协议转让） 签署日期：2024 年 9 月 29 日 1 第一节 释义 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收购管理办法》"）、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》（以下简称 "《第15号准则》"）及相关的法律法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反信息 披露义务人章程或者内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购管理办法》《第15号准则》的规定，本报告书已全面披 露了信息披露义务人在江苏爱朋医疗科技股份有 ...

关于控股股东、实际控制人部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于近日收到公司控股股 东、实际控制人王凝宇先生通知，获悉其所持有本公司的部分股份办理了质押展 期，具体事项如下： 一、股东股份质押基本情况 证券代码：300753 证券简称：爱朋医疗 公告编号：2024-038 江苏爱朋医疗科技股份有限公司 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 持股数量 | 持股比 | 本次质押前 | 本次质押后 | 占其所 | 占公司 | 情况 | | 情况 | | | 名称 | （股） | 例 | 质押股份数 | 质押股份数 | 持股份 | 总股本 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | | | 量（股） | 量（股） | 比例 | 比例 | 限售和冻结 | 押股份 | 限售和冻结 | 押 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a year-on-year increase of 15%[2]. - The company has set a revenue guidance of RMB 1.1 billion for the full year 2024, reflecting an expected growth of 10%[3]. - The company's operating revenue for the first half of 2024 was ¥179,465,240.74, a decrease of 4.89% compared to ¥188,697,092.52 in the same period last year[13]. - Net profit attributable to shareholders was ¥8,893,500.73, representing a significant increase of 221.31% from ¥2,767,900.36 in the previous year[13]. - Basic earnings per share rose to ¥0.0706, up 221.31% from ¥0.0220 in the same period last year[13]. - The net cash flow from operating activities improved to ¥5,826,943.34, a 255.15% increase compared to -¥1,956,532.19 in the previous year[13]. - The company's total revenue from sales of goods and services reached 105,698,328.58 CNY, significantly up from 63,804,220.73 CNY in the first half of 2023, indicating a growth of approximately 65%[146]. - The company reported a total profit of CNY 36,624,434.27 for the first half of 2024, up from CNY 6,552,611.58 in the same period last year, indicating an increase of approximately 469.5%[143]. User and Market Data - User data indicates that the number of active users of the company's medical devices reached 1.2 million, up 20% compared to the same period last year[3]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[3]. - The demand for pain management devices is expected to grow, with the market projected to reach $14.55 billion by 2026, growing at a CAGR of 13.8% from 2019 to 2026[18]. - Over 300 million people in China suffer from chronic pain, with an annual increase of 10 to 20 million patients[19]. - The market for nasal care devices is expected to expand due to the rising incidence of upper respiratory infections, with 110.01 million ENT visits recorded in 2021[19]. Product Development and Innovation - New product launches include a state-of-the-art pain management device, which is projected to contribute RMB 100 million in sales by the end of 2024[3]. - Research and development expenses increased by 30% to RMB 50 million, focusing on innovative medical technologies[3]. - The company aims to establish a pain management product ecosystem, focusing on postoperative pain, labor pain, and cancer pain management[28]. - The company has developed a series of high-precision intelligent pain management products, including microcomputer infusion pumps and wireless pain management systems, targeting acute and chronic pain management[28]. - The company is actively involved in the development of new standards for portable electric infusion pumps, positioning itself as a key player in the industry[25]. Strategic Acquisitions and Partnerships - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of RMB 200 million allocated for this purpose[3]. - The company has established a strategic partnership with Shanghai Pharmaceuticals to enhance collaboration in medical research and hospital operations[38]. - The company has invested in Changzhou Ruishen'an Medical Equipment Co., focusing on brain-machine interface technology for chronic pain management, establishing a foundation for future strategic synergies[30]. Financial Management and Investments - The company has made a significant equity investment of CNY 2,000,000.00 in Aizhong Yingju, acquiring a 90% stake[70]. - The total amount of raised funds is 262.93 million RMB, with 89.69 million RMB invested during the reporting period[75]. - The company has established four dedicated accounts for raised funds, ensuring compliance with regulatory requirements[76]. - The company has committed a total investment of CNY 26,293 million for various projects, with a cumulative investment of CNY 18,975.9 million as of the report date, representing 55.40% of the planned investment progress[77]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[2]. - The company faces significant industry policy risks due to new regulations from the National Medical Products Administration, particularly regarding the centralized procurement of infusion pumps across 28 provinces, which may impact operational models and competitive dynamics[88]. - The company acknowledges the high costs and long registration cycles associated with new product development in the medical device industry, which could affect profitability if market trends are not accurately predicted[89]. Corporate Governance and Social Responsibility - The company has not reported any changes in its registered address or contact information during the reporting period[10]. - The company emphasizes environmental protection as a core value, adhering to national regulations and improving its environmental management system[98]. - The company actively recruits disabled employees, providing equal employment opportunities and a supportive work environment[107]. - The company participated in various social responsibility initiatives, including donating medical equipment to support grassroots healthcare[106]. Quality Control and Compliance - The company has established a comprehensive quality control system covering all stages from R&D to after-sales service, achieving ISO9001 and ISO13485 certifications[58]. - The company adheres strictly to quality management regulations and aims to enhance its quality management system to prevent product quality issues[90]. - There were no discrepancies between the financial reports prepared under international accounting standards and those under Chinese accounting standards for the reporting period[14]. Shareholder Information - The company does not plan to distribute cash dividends or issue bonus shares for the current fiscal year[2]. - The company held its annual general meeting on May 20, 2024, with a participation rate of 47.06%[94]. - The total number of shareholders at the end of the reporting period was 12,146, with 5% shareholders holding 34.22% of the shares[126].

编制单位：江苏爱朋医疗科技股份有限公司 单位：人民币万元 | | | 占用方与上市 | 上市公司核 | 2024 年期初 | 2024 年 1-6 占用累计发生 | 月 | 2024 年 1-6 | 月 | 2024 年 1-6 月 | | 2024 年上半年 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 公司的关联关 | 算的会计科 | 占用资金余额 | 金额（不含利 | | 占用资金的利 | | 偿还累计发生 | | 期末 | 原因 | 占用性质 | | | | 系 | 目 | | 息） | | 息（如有） | | 金额 | | 占用资金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | | | | - | | 前控股股东、实际控 ...